Literature DB >> 25161379

SEDDS of gliclazide: Preparation and characterization by in-vitro, ex-vivo and in-vivo techniques.

Tanzina Sharmin Nipun1, S M Ashraful Islam1.   

Abstract

In the study, self emulsifying drug delivery system (SEDDS) of gliclazide, a poorly soluble drug, was developed and evaluated by in-vitro, ex-vivo and in-vivo techniques. Oil and surfactant were screened out according to their solubilizing capacity. Among the tested components Transcutol HP and Tween-80 showed good solubilizing capacity. These two components were used in different ratios to prepare gliclazide SEDDS. The SEDDS formulations were transparent and clear. Droplet size of the emulsion was determined by Laser Diffraction Technology of Malvern. Formulation F1 containing 1:1 (m/m) mixture of Transcutol HP/Tween-80 showed minimum mean droplet size (50.959 μm). In-vitro drug release from F1 was higher (99% within 20 min) than other formulations. The developed SEDDS was also evaluated for ex-vivo permeability profile by using chicken intestinal sac. Formulation F1 showed optimal drug diffusion. In-vivo performance of SEDDS was evaluated in albino mice using plasma glucose level as a pharmacodynamic marker parameter. The test formulation (F1) showed significant reduction in plasma glucose level, after oral administration. So SEDDS may be an alternative technique for the oral administration of gliclazide.

Entities:  

Keywords:  Dissolution; Gliclazide; Particle size analysis; Solubility analysis; Transcutol HP; Tween-80

Year:  2013        PMID: 25161379      PMCID: PMC4142356          DOI: 10.1016/j.jsps.2013.06.001

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  12 in total

Review 1.  In vitro models of the intestinal barrier. The report and recommendations of ECVAM Workshop 46. European Centre for the Validation of Alternative methods.

Authors:  E Le Ferrec; C Chesne; P Artusson; D Brayden; G Fabre; P Gires; F Guillou; M Rousset; W Rubas; M L Scarino
Journal:  Altern Lab Anim       Date:  2001 Nov-Dec       Impact factor: 1.303

2.  Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate.

Authors:  Ashok R Patel; Pradeep R Vavia
Journal:  AAPS J       Date:  2007-10-26       Impact factor: 4.009

3.  Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment.

Authors:  T R Kommuru; B Gurley; M A Khan; I K Reddy
Journal:  Int J Pharm       Date:  2001-01-16       Impact factor: 5.875

Review 4.  Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism.

Authors:  B J Aungst
Journal:  J Pharm Sci       Date:  1993-10       Impact factor: 3.534

Review 5.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.

Authors:  C W Pouton
Journal:  Eur J Pharm Sci       Date:  2000-10       Impact factor: 4.384

6.  Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system.

Authors:  M J Ginski; J E Polli
Journal:  Int J Pharm       Date:  1999-01-15       Impact factor: 5.875

7.  Formulation of a self-emulsifying system for oral delivery of simvastatin: in vitro and in vivo evaluation.

Authors:  Pradeep Patil; Vandana Patil; Anant Paradkar
Journal:  Acta Pharm       Date:  2007-03       Impact factor: 2.230

Review 8.  Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.

Authors:  K J Palmer; R N Brogden
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

9.  Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).

Authors:  Eman Atef; Albert A Belmonte
Journal:  Eur J Pharm Sci       Date:  2008-07-25       Impact factor: 4.384

Review 10.  Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.

Authors:  A D Harrower
Journal:  J Diabetes Complications       Date:  1994 Oct-Dec       Impact factor: 2.852

View more
  6 in total

1.  Self-Emulsifying Drug Delivery System Enhances Tissue Distribution of Cinnamaldehyde by Altering the Properties of the Mucus Layer.

Authors:  Liu Liu; Wenxuan Cao; Mengqiu Xia; Chunling Tian; Wenqing Wu; Ye Cai; Xiaoqin Chu
Journal:  AAPS PharmSciTech       Date:  2022-09-21       Impact factor: 4.026

2.  Betahistine dihydrochloride transdermal delivery via optimized thermosensitive gels: percutaneous absorption evaluation using rat growth as a biomarker.

Authors:  Mohammed Hassan Elkomy; Shahira F El-Menshawe; Adel Ahmed Ali; Abdelkhalik Ali Halawa; Ahmed S G Srag El-Din
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

3.  Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.

Authors:  Mehran Mesgari Abbasi; Hadi Valizadeh; Hamed Hamishehkar; Parvin Zakeri-Milani
Journal:  Res Pharm Sci       Date:  2016 May-Jun

4.  A novel transdermal nanoethosomal gel of betahistine dihydrochloride for weight gain control: in-vitro and in-vivo characterization.

Authors:  Shahira F El-Menshawe; Adel Ahmed Ali; Abdelkhalk Ali Halawa; Ahmed Sg Srag El-Din
Journal:  Drug Des Devel Ther       Date:  2017-11-28       Impact factor: 4.162

5.  Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study.

Authors:  Alaa Mohamed Nazief; Passainte Saber Hassaan; Hoda Mahmoud Khalifa; Magda Samir Sokar; Amal Hassan El-Kamel
Journal:  Int J Nanomedicine       Date:  2020-02-18

6.  A novel self-nanoemulsifying drug delivery system for curcumin used in the treatment of wound healing and inflammation.

Authors:  Niyaz Ahmad; Rizwan Ahmad; Ali Al-Qudaihi; Salman Edrees Alaseel; Ibrahim Zuhair Fita; Mohammed Saifuddin Khalid; Faheem Hyder Pottoo; Srinivasa Rao Bolla
Journal:  3 Biotech       Date:  2019-09-09       Impact factor: 2.893

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.